Navigation Links
Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
Date:4/16/2009

SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire/ -- Proteolix, Inc. today announced the appointment of Craig C. Parker to the post of Senior Vice President, Finance and Corporate Development and Chief Financial Officer (CFO), and the expansion of the company's clinical development and regulatory leadership team with the appointment of Michael G. Kauffman, M.D., Ph.D., to the post of Chief Medical Officer (CMO) and Albert L. Kraus, Ph.D., to the newly-created position of Vice President, Regulatory Affairs and Quality Assurance.

"We are pleased to welcome Craig Parker and Drs. Kauffman and Kraus to the Proteolix team at this important stage in the company's maturation. Craig's rich experience in finance, management and forming partnerships make him a superb addition as we advance our lead anti-cancer product, carfilzomib, into late-stage clinical studies," said John A. Scarlett, M.D., Proteolix's President and Chief Executive Officer. "In addition, the expansion of our clinical development leadership team reflects the excellent progress made in carfilzomib's development. Michael's background as program leader in the development of VELCADE, combined with his knowledge of carfilzomib as a prior member of the Proteolix Board of Directors, and Albert's experience in regulatory affairs and shepherding the late-stage development of new oncology therapeutics, will be invaluable as Proteolix advances carfilzomib through pivotal clinical trials."

Craig C. Parker

Senior Vice President, Finance and Corporate Development and Chief Financial Officer

Mr. Parker brings more than 15 years of finance and business development leadership in the biotechnology industry to Proteolix. In this newly-created role, he is responsible for the company's financial operations, business development, corporate strategic planning and legal affairs.

Mr. Parker's career includes 12 years as a Wall Street resear
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... May 21 Martek Biosciences,Corporation (Nasdaq: MATK ) ... UBS Global Generic and Specialty Pharmaceuticals Conference in,London. The ... at the Waldorf,Hilton, Aldwych, London. Steve Dubin, CEO will ... EDT (2:00 p.m. London Time)., Interested parties may ...
... Still River Systems announces,the successful development and operation ... of the development of its Monarch250(TM) proton,therapy system. ... conclusively,demonstrates that cyclotrons at this high field strength ... By increasing the operating,magnetic field, Still River Systems ...
... N.J., May 21 Aton Pharma, Inc., a ... signed a,marketing and distribution agreement with PharmaLink Asia ... into several countries in Asia and,Australia., "This ... we execute,our mission to expand access to our ...
Cached Biology Technology:Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Aton Pharma Announces Distribution Partnership in the Asia Pacific Region 2
(Date:7/23/2014)... , July 24, 2014 Pfenex Inc. (NYSE ... offering of 8,333,333 shares of its common stock at a ... Pfenex has granted the underwriters a 30-day option to purchase ... initial public offering price. The shares are expected to begin ... the symbol "PFNX". William Blair & ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... crow and the pitcher, a thirsty bird happens upon a ... it, he finds the water level out of his reach. ... drops pebbles into it one at a time ... his fill. , Highlighting the value of ingenuity, the fable ... brute force. It also characterizes crows as pretty resourceful problem ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... Researchers have identified a gene that appears to increase a ... type of Alzheimer,s disease. The research will be presented as ... of Neurology,s 62nd Annual Meeting in Toronto, April 10 ... six. "Only recently have common variants in genes ...
... who co-piloted the historic 1960 deep-sea voyage of the Trieste, will ... on at 10 a.m. April 15 at the U.S. Navy Museum ... to have visited the Challenger Deep the deepest part of ... navigating the bathyscaphe (deep submergence vehicle) Trieste 35,810 feet down to ...
... 13, 2010 -- Two chemists at The Scripps Research Institute have ... that turns itself on or off as it detects metallic ions ... the April 19, 2010 issue of the International Edition of the ... tool for controlling tiny reactions in the test tube, and it ...
Cached Biology News:New gene associated with increased risk of Alzheimer's disease 2New nano-tool synthesized at Scripps Research Institute 2
... Visualizer DX's sensitivity of DNA detection has been ... in an agarose gel can be detected > ... can be purified by organic solvent extraction or ... kits worked well.) DNA excised from agarose ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Small space saving design - ideal for personal ... models: , - 3D gyratory action SSM3 , ... speed control and built-in timer , Optional tier system ... ideal where gentle mixing is required, either on the ...
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
Biology Products: